SLRX: Salarius Pharmaceuticals, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 2.16
Enterprise Value ($M) -3.45
Book Value ($M) 5.29
Book Value / Share 1.23
Price / Book 0.41
NCAV ($M) 5.22
NCAV / Share 1.21
Price / NCAV 0.41

Profitability (mra)
Return on Invested Capital (ROIC) -2.25
Return on Assets (ROA) -1.25
Return on Equity (ROE) -2.26

Liquidity (mrq)
Quick Ratio 5.02
Current Ratio 5.02

Balance Sheet (mrq) ($M)
Current Assets 6.52
Assets 6.59
Liabilities 1.30
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income -12.89
Net Income -12.54
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -12.85
Cash from Investing 0.00
Cash from Financing 6.64

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)
Change
(%)
02-14 13G Armistice Capital, Llc 9.99
10-27 13D Lee Elvin Sanghwan 6.09

Top 13F Investors Shares
(1000)
Change
(%)
Value
($1000)
Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-03-22 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ———————————— (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITI
2023-11-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION R
2023-08-10 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT
2023-05-11 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPOR

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-04-12 5,163 14,660 35.22
2024-04-11 508 10,362 4.90
2024-04-10 1,419 31,754 4.47
2024-04-09 2,735 51,764 5.28
2024-04-08 1,066 40,002 2.66

(click for more detail)

Similar Companies
SCLX – Scilex Holding Company SEEL – Seelos Therapeutics, Inc.
SHPH – Shuttle Pharmaceuticals Holdings, Inc. SLS – SELLAS Life Sciences Group, Inc.
SMFL – Smart for Life, Inc.


Financial data and stock pages provided by
Fintel.io